Nancy Holekamp, MD

Articles by Nancy Holekamp, MD

Advice to Physicians Treating Geographic Atrophy

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

January 9th 2023

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp share takeaways for health care professionals taking care of patients with geographic atrophy and earlier stages of age-related macular degeneration.

Bringing Ocular Imaging to Primary Care Practices

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

January 9th 2023

Eleonora M. Lad, MD, PhD, shares how advances in ocular imaging, including AI tools, can improve diagnosis of geographic atrophy going forward.

Improving Referral for Geographic Atrophy

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

January 3rd 2023

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss the need to improve the referral process through educating physicians about geographic atrophy.

Introduction of New Geographic Atrophy Treatments in Practice

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

January 3rd 2023

A panel of experts discuss what clinics need to consider when introducing new geographic atrophy treatments in their practice.

Ensuring Adherence to Geographic Atrophy Treatment

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

December 26th 2022

Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp share insights to ensure adherence to therapy once started.

Guidance for Treatment Selection in Geographic Atrophy

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

December 26th 2022

An expert panel discusses the role of complement C3 vs C5 therapies and provides guidance for treatment selection in geographic atrophy.

Other Complement Inhibitors for Geographic Atrophy Treatment

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

December 19th 2022

Drs Eleonora M. Lad and Nancy M. Holekamp review other emerging treatment options for geographic atrophy.

Pegcetacoplan and Monitoring in Geographic Atrophy

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

December 19th 2022

A panel of experts comments on the safety data of pegcetacoplan in geographic atrophy and their approach to monitoring patients.

Treatment of Both Eyes and Subfoveal Lesions in Geographic Atrophy

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

December 12th 2022

Eleonora M. Lad, MD, PhD, shares her approach to treating subfoveal lesions and geographic atrophy in both eyes.

Frequency of Pegcetacoplan Administration for Geographic Atrophy Treatment

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

December 12th 2022

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss pegcetacoplan dose frequency in treating geographic atrophy.

Pegcetacoplan for Treatment of Geographic Atrophy

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

December 5th 2022

A panel of experts discuss clinical data with pegcetacoplan for treatment of geographic atrophy.

Pathophysiology, Treatment Targets and Options in Geographic Atrophy

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

December 5th 2022

An expert panel provides an overview of pathophysiological changes in geographic atrophy, ongoing research and promising new treatment options.

Geographic Atrophy Management in Clinical Practice

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

November 28th 2022

Jaynath R. Sridhar, MD, shares insights into managing geographic atrophy in his clinic given that there is no FDA-approved treatment.

Imaging Modalities in Geographic Atrophy

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

November 28th 2022

David R. Lally, MD, and Jayanth Sridhar, MD, comment on the use of imaging tools to for diagnosis and measuring progression of geographic atrophy.

Progression of Geographic Atrophy Over Time

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

November 21st 2022

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss progression of geographic atrophy and what should be discussed with patients.

Discussing Management of Age-Related Macular Degeneration (AMD) with the Patient

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

November 21st 2022

A panel of experts shares their thoughts on communicating with patients with mild, intermediate and neovascular age-related macular degeneration about treatment, compliance, and the potential to develop geographic atrophy.

Impact of Geographic Atrophy on the Caregiver

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

November 14th 2022

Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp discuss numerous ways geographic atrophy can impact the caregiver’s quality of life.

Disease Burden and Tools to Manage Geographic Atrophy

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

November 14th 2022

An expert panel reviews the burden of geographic atrophy, and the various tools patients can use to help manage that burden.

Patient Communication Regarding Visual Function in Geographic Atrophy

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

November 7th 2022

Jayanth Sridhar, MD, Nancy M. Holekamp, MD, FASRS, and David R. Lally, MD, share their thoughts on measuring visual changes to determine how their patients’ geographic atrophy is progressing.

Overview of Geographic Atrophy (GA)

ByEleonoroa M. Lad, MD, PhD,David R. Lally, MD,Jayanth Sridhar, MD,Nancy Holekamp, MD

November 7th 2022

Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp provide an overview of age-related macular degeneration and risk of developing geographic atrophy (GA).

The Future of Treatment for Diabetic Macular Edema

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

February 3rd 2022

Dr Theodore Leng discusses what the future may hold for patients with diabetic macular edema.

Emerging Treatment Options for Diabetic Macular Edema

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 27th 2022

Dr. Ehsan Rahimy describes the emerging treatment options for diabetic macular edema.

Diabetic Macular Edema: Faricimab

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 27th 2022

Joseph M. Coney, MD, provides an overview of the drug faricimab for treating diabetic macular edema.

Anti-VEGF Agents and Diabetic Retinopathy Severity Score

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 20th 2022

Retina specialists review clinical trial data on the impact of anti-VEGF agents on diabetic retinopathy severity scores.

Maintenance Treatment for Diabetic Macular Edema

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 20th 2022

Key opinion leaders describe maintenance treatments for diabetic macular edema and provide an overview of the PANORAMA study.

Considerations for Switching Diabetic Macular Edema Treatments

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 17th 2022

Ehsan Rahimy, MD, and Theodore Leng, MD, FACS, discuss how to assess patient response to treatment and when to switch agents.

Reviewing Anti-VEGF Agents in Clinical Practice

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 17th 2022

Dr Joseph M. Coney reviews his personal experience using anti-VEGF agents to treat diabetic macular edema in his clinical practice.

Diabetic Macular Edema: Limitations of Anti-VEGF Agents

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 17th 2022

Retina experts discuss the limitations of anti-VEGF agents in treating diabetic macular edema.

Anti-VEGF Agents for Diabetic Macular Edema

ByNancy Holekamp, MD,Joseph M. Coney, MD,Theodore Leng, MD, FACS,Ehsan Rahimy, MD

January 17th 2022

Theodore Leng, MD, FACS, describes the currently available anti-VEGF agents for treating diabetic macular edema and what factors to consider when choosing a therapy.